Skip to main content
Bioinformation logoLink to Bioinformation
. 2025 Feb 28;21(2):274–281. doi: 10.6026/973206300210274

Molecular docking analysis of phytochemicals from Soothaga Thadai Kudineer with cyp-17α-hydroxylase enzyme

Saraswathi Balasubramaniyan 1,*, Siva Annamalai 2,*, Deepa Ravichandran 1,*, Vinu Bharathi Balasubramaniam 1,*, Vinodini Ramamoorthy 2,*, Shunmugaram Shenbagaraj 3,*
PMCID: PMC12044178  PMID: 40322708

Abstract

Polycystic ovarian syndrome (PCOS) affects 9.2% of women of reproductive age and has doubled in prevalence, rising from 6 million cases in 1990 to 12.13 million in 2019. PCOS is characterized by symptoms like irregular periods, acne, hirsutism, male-pattern baldness, weight gain, mood swings and infertility. PCOS is primarily associated with elevated androgen levels. The use of Indian Soothaga Thadai Kudineer for managing PCOS is well documented. Therefore, it is of interest to report the Molecular docking analysis of phytochemicals from Indian Soothaga Thadai Kudineer with cyp-17α-hydroxylase enzyme (CYP17). Analysis shows that phytochemicals such as gingerenone A, chlorogenic acid and piperine present in Soothaga Thadai Kudineer exhibit strong binding affinities to the enzyme suggesting their potential as CYP17 inhibitors for further validation and consideration.

Keywords: Soothaga Thadai Kudineer, siddha medicine, Molecular docking

Background:

Polycystic ovary syndrome (PCOS) is a prevalent condition, affecting approximately 9.2% of women of reproductive age and is one of the leading causes of infertility. A study highlights the significant rise in the number of women diagnosed with PCOS, from 6 million in 1990 to 12.13 million in 2019, underscoring its growing impact on women's health [1, 2]. Hormonal imbalances, irregular periods, excess androgen levels and cysts in the ovaries are the features of PCOS [3]. Clinical symptoms include 'heavy, long, intermittent, unpredictable or absent periods, infertility, acne or oily skin, excessive hair on the face (Hirsutism) or body, male-pattern baldness or hair thinning, weight gain especially around the belly, mood swings' [4] and leads to other health conditions including 'Type 2 Diabetes Mellitus, Hypertension, Dyslipidaemia and heart disease' [5]. The primary symptom of PCOS in the majority of patients is elevated androgen levels. A particular androgen-regulating protein, P450 17α hydroxylase, is encoded by the promoter region of the enzyme CYP 17. This protein is crucial for both obesity and reproductive function [6]. The microsomal enzyme CYP17 is required for the synthesis of gonadal and adrenal steroids. It possesses lyase and hydroxylase functions, also expresses itself in gonadal tissues as well as the adrenal cortex's zona fasciculata and zona recticulars. Four major steroid hormones, including cortisol, testosterone, estradiol and DHEA, are formed primarily by CYP17 alpha. Firstly it acts on progesterone and pregnenolone at the C17 position, resulting in hydroxylation to form '17-hydroxypregnenolone' and '17-hydroxyprogesterone'. It then splits the 'C17-C20 bond of 17-hydroxypregnenolone' and '17-hydroxyprogesteron' to form androstenedione and dehydroepiandrosterone [7]. An imbalance of steroidogenesis in the adrenal glands and ovaries causes hypoandrogenism in PCOS. Androgen is converted to testosterone more quickly as a result of the overexpression of the CYP17 encoding gene [8]. The use of the Indian Soothaga Thadai Kudineer for managing PCOS is well documented. Therefore, it is of interest to report the Molecular docking analysis of phytochemicals from Indian Soothaga Thadai Kudineer with cyp-17α-hydroxylase enzyme (CYP17).

Materials and Methods:

Study drug:

The Ingredients and Phytochemicals of Siddha Polyherbal formulation Soothaka Thadai Kudineer [9, 10, 11, 12, 13, 14, 15, 16, 17-18] were tabulated in Table 1.

Table 1. Ingredients of the Soothaka Thadai Kudineer and their selected phytochemicals.

S. No Ingredients Family Phytochemicals
Botanical Name Vernacular Name
1. Trachyspermum ammi Linn. Omam Apiaceae Carvone [10]
2. Bambusa arundinacea Linn. Munkililai Poaceae Chlorogenic acid [11]
3. Crataeva religiosa G.Frost. Mavilinkappattai Capparaceae β-caryophyllene [12]
4. Smilax china Linn. Parankipattai Liliaceae Kaempferitrin [13]
5. Zingiber officinale Roscoe. Cukku Zingiberacea Gingerenone-A [14]
6. Piper longum Linn. Tippili Piperaceae Piperine [15]
7. Plumbago indica Linn. Cittiramulaver, verpattai Plumbaginaceae Plumbagin [16]
8. Nigella sativa Linn. Karuñcirakam Ranunculaceae Oleic acid [17]
9. Anethum graveolens Linn. Catakuppai Apiaceae Anethole [18]

Target protein preparation:

The protein data bank was used to obtain the crystalline structure of the target protein enzyme, CYP-17α-hydroxylase (Figure 1 - see PDF), with PDB number 3RUK. A protein clean-up procedure was then carried out and the necessary missing hydrogen atom was added.

Ligand preparation:

The Auto-dock program was used to assess how differently oriented the lead molecules were in relation to the target proteins and the interaction study analysis was used to determine which dock posture was optimal. 2D and 3D structures of ligands were depicted in Figure 2 (see PDF) and their properties were tabulated in Table 2.

Table 2. Ligand properties of the compounds selected for docking analysis.

S. No Compound Molar weight g/mol Molecular Formula H Bond Donor H Bond Acceptor Rotatable bonds
1. Carvone 150.221 g/mol C10H14O 0 1 1
2. Chlorogenic acid 354.31 g/mol C16H18O9 6 9 5
3. β-caryophyllene 204.35 g/mol C15H24 0 0 0
4. Kaempferitrin 578.5 g/mol C27H30O14 8 14 5
5. Gingerenone-A 356.4 g/mol C21H24O5 2 5 9
6. Piperine 285.34 g/mol C17H19NO3 0 3 3
7. Plumbagin 188.182 g/mol C11H8O3 1 3 0
8. Oleic acid 282.5 g/mol C18H34O2 1 2 15
9. Anethole 148.20g/mol C10H12O 0 1 2

Docking procedure:

For the extracted phytocomponents, docking computations were performed against the target enzyme, CYP-17α-hydroxylase. Using Auto Dock Tools, essential hydrogen atoms, Kollman united atom type charges and solvation parameters were incorporated. Affinity (grid) maps of xx Å grid points and 0.375 Å spacing were generated using the Auto grid program [19]. The dielectric functions dependent on distance and the Auto Dock parameter set were utilized to compute the electrostatic and van der Waals terms, respectively. Using the Solis & Wets local search technique and the Lamarckian genetic algorithm (LGA), docking simulations were carried out [20]. The ligand molecules' initial orientation, location as well as and torsions were all randomly determined. During docking, all rotatable torsions were freed. Every docking experiment was the result of two separate runs that were intended to end after a maximum of 250000 energy assessments. 150 were the target population. A translational step of 0.2 Å and quaternion and torsion steps of 5 were used in the search.

Results:

The Molecular docking analysis of nine compounds against CYP-17α-hydroxylase (PDB ID: 3RUK) reveals varying levels of binding affinities and interactions with specific amino acid residues. Gingerenone-A showed the highest binding affinity, with an estimated free energy of -9.07 kcal/mol and an inhibition constant (Ki) of 224.04 nM, suggesting it could be a potent inhibitor. Compounds like Chlorogenic acid and Piperine also demonstrated strong binding with inhibition constants in the nanomolar range, indicating significant inhibitory potential. Kaempferitrin and Oleic acid, on the other hand, displayed much weaker affinities, with higher Ki values, suggesting limited effectiveness as inhibitors. Across these compounds, residues such as ALA, THR, VAL and ILE were frequently involved, suggesting their importance in the ligand binding and stabilization processes within the enzyme's active site. The compounds also varied in their electrostatic and total intermolecular energies, with interaction surfaces ranging from 303.81 to 734.107, reflecting differences in the extent of enzyme surface engagement. This study highlights Gingerenone-A as a promising candidate for further exploration as a CYP-17α-hydroxylase inhibitor, with Chlorogenic acid and Piperine also showing potential as effective inhibitors. The docking poses, 2D Interaction Plot Analysis and Hydrogen bond plotting were depicted in Figure 3 (see PDF), Figure 4 (see PDF), & Figure 5 (see PDF) respectively. The results of the Molecular docking were tabulated in Table 3 & Table 4.

Table 3. Molecular docking against cyp- 17α-hydroxylase.

S. No Compound Est. Free Energy of Binding Est.Inhibition Constant, Ki Electrostatic Energy Total Intermolec. Energy Interact. Surface
1. Carvone -6.17 kcal/mol 29.93 uM -0.03 kcal/mol -6.47 kcal/mol 362.976
2. Chlorogenic acid -8.43 kcal/mol 663.72 nM -0.08 kcal/mol -7.86 kcal/mol 536.859
3. β-caryophyllene -8.27 kcal/mol 872.02 nM -0.01 kcal/mol -8.27 kcal/mol 430.14
4. Kaempferitrin -4.19 kcal/mol 845.07 uM -0.26 kcal/mol -4.22 kcal/mol 734.107
5. Gingerenone-A -9.07 kcal/mol 224.04 nM -0.18 kcal/mol -8.18 kcal/mol 555.376
6. Piperine -8.53 kcal/mol 559.93 nM -0.04 kcal/mol -8.10 kcal/mol 456.344
7. Plumbagin -6.14 kcal/mol 31.59 uM -0.03 kcal/mol -6.44 kcal/mol 369.403
8. Oleic acid -3.94 kcal/mol 1.29 mM -0.01 kcal/mol -4.24 kcal/mol 303.81
9. Anethole -5.25 kcal/mol 142.87 uM -0.12 kcal/mol -5.84 kcal/mol 378.878

Table 4. The phytochemicals interact with amino acid residues to inhibit cyp-17α-hydroxylase.

Compounds Interaction Amino Acid Residues
Carvone 0 302 306 366 367 371 483
ALA THR VAL ALA ILE VAL
Chlorogenic acid 2 105 113 114 205 209 239 298 302 305 306 366 367 482 483
ALA ALA PHE ILE LEU ARG ASP ALA GLU THR VAL ALA VAL VAL
β-caryophyllene 0 302 306 366 367 371 482 483
ALA THR VAL ALA ILE VAL VAL
Kaempferitrin 3 105 113 114 201 202 205 209 239 294 298 302 305 306 366 371 483
ALA ALA PHE TYR ASN ILE LEU ARG THR ASP ALA GLU THR VAL ILE VAL
Gingerenone-A 2 113 114 202 205 206 209 239 298 302 305 306 482 483
ALA PHE ASN ILE ILE LEU ARG ASP ALA GLU THR VAL VAL
Piperine 0 113 114 302 305 306 371 483
ALA PHE ALA GLU THR ILE VAL
Plumbagin 0 113 114 302 306 366 367 371 482
ALA PHE ALA THR VAL ALA ILE VAL
Oleic acid 2 201 202 205 239 297 298
TYR ASN ILE ARG GLY ASP
Anethole 0 113 298 302 306 366 367 371
ALA ASP ALA THR VAL ALA ILE

Discussion:

Polycystic ovarian syndrome is treated with a variety of synthetic hormones like Oral Contraceptive Pills (OCP) which leads to adverse effects like venous thromboembolism (VTE), Thrombolytic shock and Myocardial Infarction [21]. Therefore, there is a need for alternative intervention to treat the ailments. The findings of this study demonstrate the potential of Soothaga Thadai Kudineer, a Siddha polyherbal formulation, in modulating the activity of the enzyme CYP17α-hydroxylase, which plays a key role in androgen biosynthesis.

Elevated levels of androgens are a primary characteristic of PCOS and CYP17α-hydroxylase is critical in regulating steroidogenesis in the ovaries and adrenal glands. The Molecular docking analysis presented in this study highlights several phytochemicals that exhibit significant binding affinities to CYP17α-hydroxylase, which suggests that they may serve as potential inhibitors of the enzyme's activity, thereby mitigating the excessive androgen production in PCOS.

Among the nine phytochemicals tested, Ginger none-A, Chlorogenic acid and Piperine exhibited the most promising interactions, with low estimated binding energies and inhibition constants (Ki). This indicates a strong binding affinity to the target protein, suggesting that these compounds may act as effective inhibitors of CYP17α-hydroxylase.

Ginger none-A demonstrated the highest binding energy (-9.07 kcal/mol) and the lowest inhibition constant (224.04 nM), making it a prime candidate for further investigation as a natural therapeutic agent for managing PCOS. The interaction of phytochemicals with key amino acid residues of the enzyme, particularly those located in the active site, further supports their potential inhibitory role. Notably, the amino acid residues ALA302, THR306, VAL366 and ILE371 were consistently involved in the binding of several phytochemicals, suggesting that these residues play a crucial role in the enzyme's catalytic function. By forming stable hydrogen bonds or hydrophobic interactions with these residues, the phytochemicals may hinder the enzyme's ability to catalyse steroid genesis, thus reducing androgen production. The presence of diverse bioactive compounds in Soothaga Thadai Kudineer indicates its potential as a multitarget therapeutic for PCOS. The polyherbal nature of this formulation could allow for a synergistic effect, where multiple phytochemicals work together to inhibit CYP17α-hydroxylase, also potentially addressing other factors of PCOS, such as inflammation, oxidative stress and insulin resistance [22].

For instance, Kaempferitrin and Chlorogenic acid have known antioxidant properties, which could further benefit individuals with PCOS by reducing oxidative damage and improving metabolic function [23, 24]. Also some studies reported that the drug Soothaga Thadai Kudineer has been found to be effective in treating Secondary Amenorrhoea and reduces the premenstrual symptoms like back pain, abdominal bloating, headache, mood swing, irritability and tension [25, 26].

However, it is important to note that while in silico docking studies provide valuable insights into the potential interactions between phytochemicals and target proteins, these results need to be validated through in vitro and in vivo studies. Further experimental research is necessary to confirm the inhibitory effects of these phytochemicals on CYP17α-hydroxylase activity in biological systems, as well as their efficacy in reducing androgen levels in PCOS patients. Additionally, the safety and bioavailability of these compounds need to be assessed to ensure that they can be effectively used as therapeutic agents.

Conclusion:

The use of Indian Soothaga Thadai Kudineer as a natural treatment for PCOS by targeting CYP17α-hydroxylase is shown. Further, phytochemicals such as gingerenone-A, chlorogenic acid and piperine present in Soothaga Thadai Kudineer exhibit strong binding affinities to the enzyme suggesting their potential as CYP17 inhibitors. It should be noted that in vitro and in vivo analysis are required for validation and consideration.

Ethical approval:

The authors declare that due to an In-silico analysis this study does not need any ethical approval.

Consent to participate:

Not applicable

Consent to publish:

Not applicable

Author contributions:

All authors have equally contributed in the manuscript preparation like concept, designing and collection of the data, as well as the writing and revision of the article.

Funding:

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Availability of data and materials:

All the data's are available with authors upon reasonable request.

Source of funding:

No funds, grants, or other support was received for this work.

Acknowledgments

None

The authors have no relevant financial or non-financial interests to disclose.

Edited by P Kangueane

Citation: Balasubramaniyan et al. Bioinformation 21(2):274-281(2025)

Declaration on Publication Ethics: The author's state that they adhere with COPE guidelines on publishing ethics as described elsewhere at https://publicationethics.org/. The authors also undertake that they are not associated with any other third party (governmental or non-governmental agencies) linking with any form of unethical issues connecting to this publication. The authors also declare that they are not withholding any information that is misleading to the publisher in regard to this article.

Declaration on official E-mail: The corresponding author declares that official e-mail from their institution is not available for all authors.

License statement: This is an Open Access article which permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License

Comments from readers: Articles published in BIOINFORMATION are open for relevant post publication comments and criticisms, which will be published immediately linking to the original article without open access charges. Comments should be concise, coherent and critical in less than 1000 words.

Bioinformation Impact Factor:Impact Factor (Clarivate Inc 2023 release) for BIOINFORMATION is 1.9 with 2,198 citations from 2020 to 2022 taken for IF calculations.

Disclaimer:The views and opinions expressed are those of the author(s) and do not reflect the views or opinions of Bioinformation and (or) its publisher Biomedical Informatics. Biomedical Informatics remains neutral and allows authors to specify their address and affiliation details including territory where required. Bioinformation provides a platform for scholarly communication of data and information to create knowledge in the Biological/Biomedical domain.

References

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

All the data's are available with authors upon reasonable request.


Articles from Bioinformation are provided here courtesy of Biomedical Informatics Publishing Group

RESOURCES